A Morphologic and Immunohistochemical Comparison of Nuclear β-Catenin Expressing Testicular Sertoli Cell Tumors and Pancreatic Solid Pseudopapillary Neoplasms Supporting Their Continued Separate Classification.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
1
7
2020
medline:
21
10
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Some recent reports suggested that many Sertoli cell tumors, not otherwise specified (SCTs-NOS) of the testis were analogs of the solid pseudopapillary neoplasm (SPN) of the pancreas. One of the most relied on pieces of information for this assertion was the shared occurrence in both neoplasms of exon 3 mutations of the CTNNB1 gene, which was reflected by nuclear β-catenin expression. We, therefore, compared the morphologic and immunohistochemical features of 18 SCTs-NOS with strong, diffuse nuclear β-catenin expression with 16 SPNs that also showed such positivity. Although there were clear similarities in the light microscopic features of these neoplasms, there were also significant differences that included, in SCT-NOS and SPN, respectively: hollow tubules (53% vs. 0%), sheet-like growth (44% vs. 94%), circumscription (79% vs. 25%), corded or trabecular patterns (81% vs. 31%), formation of papillae or pseudopapillae (24% vs. 69%), growth in nests or clusters (94% vs. 50%), perivascular pseudorosettes (13% vs. 56%), and rhabdoid cytology (6% vs. 50%). Commonly shared morphologic features included signet-ring cells, pale or foamy cytoplasm, myxoid stroma, cyst formation, perivascular hyalinization, and globular or band-like basement membrane deposits. On immunohistochemical study, sex cord markers were frequently positive in SCTs-NOS (steroidogenic factor-1-94%; FOXL2-87%; SOX9-69%; calretinin-60%; Wilms tumor-1-38%; inhibin-29%) whereas all of these markers were negative in the SPNs. We conclude that even though SCT-NOS and SPN share some morphologic features and nuclear immunoreactivity for β-catenin, there remain differences, both morphologically and immunohistochemically, between these neoplasms to the degree that SCT-NOS should not be equated with pancreatic SPN.
Identifiants
pubmed: 32604170
doi: 10.1097/PAS.0000000000001527
pii: 00000478-202008000-00009
doi:
Substances chimiques
Biomarkers, Tumor
0
CTNNB1 protein, human
0
beta Catenin
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1082-1091Références
Michalova K, Michal M, Sedivcova M, et al. Solid pseudopapillary neoplasm (SPN) of the testis: comprehensive mutational analysis of 6 testicular and 8 pancreatic SPNs. Ann Diagn Pathol. 2018;35:42–47.
Michalova K, Michal M Jr, Kazakov DV, et al. Primary signet ring stromal tumor of the testis: a study of 13 cases indicating their phenotypic and genotypic analogy to pancreatic solid pseudopapillary neoplasm. Hum Pathol. 2017;67:85–93.
Michal M, Bulimbasic S, Coric M, et al. Pancreatic analogue solid pseudopapillary neoplasm arising in the paratesticular location. The first case report. Hum Pathol. 2016;56:52–56.
Young RH, Koelliker DD, Scully RE. Sertoli cell tumors of the testis, not otherwise specified: a clinicopathologic analysis of 60 cases. Am J Surg Pathol. 1998;22:709–721.
Fichtner A, Fisseler-Eckhoff A, Kramer W, et al. Primary signet-ring stromal tumour of the testis: case report with literature review. APMIS. 2019;127:45–49.
Michal M, Hes O, Kazakov DV. Primary signet-ring stromal tumor of the testis. Virchows Arch. 2005;447:107–110.
Zhu P, Duan Y, Ao Q, et al. Microcystic stromal tumor of testicle: first case report and literature review. Cancer Res Treat. 2018;50:1452–1457.
Perrone F, Bertolotti A, Montemurro G, et al. Frequent mutation and nuclear localization of beta-catenin in Sertoli cell tumors of the testis. Am J Surg Pathol. 2014;38:66–71.
Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161–E171.
Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33:354–366.
Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011;35:484–494.
Kao CS, Idrees MT, Young RH, et al. “Dissecting gonadoblastoma” of Scully: a morphologic variant that often mimics germinoma. Am J Surg Pathol. 2016;40:1417–1423.
Kao CS, Ulbright TM, Idrees MT. Gonadoblastoma: an immunohistochemical study and comparison to Sertoli cell nodule with intratubular germ cell neoplasia, with pathogenetic implications. Histopathology. 2014;65:861–867.
Buell-Gutbrod R, Ivanovic M, Montag A, et al. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol. 2011;14:391–395.
Kao CS, Cornejo KM, Ulbright TM, et al. Juvenile granulosa cell tumors of the testis: a clinicopathologic study of 70 cases with emphasis on its wide morphologic spectrum. Am J Surg Pathol. 2015;39:1159–1169.
Egashira N, Takekoshi S, Takei M, et al. Expression of FOXL2 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2011;24:765–773.
Fanburg-Smith JC, Auerbach A, Marwaha JS, et al. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, SOX9, and osteocalcin immunostaining of 22 cases. Hum Pathol. 2010;41:653–662.
Cajaiba MM, Jianhua L, Goodman MA, et al. SOX9 expression is not limited to chondroid neoplasms: variable occurrence in other soft tissue and bone tumors with frequent expression by synovial sarcomas. Int J Surg Pathol. 2010;18:319–323.
Matsuura S, Ishii T, Endo M, et al. Epithelial and cartilaginous differentiation in clear cell chondrosarcoma. Hum Pathol. 2013;44:237–243.
Mesquita P, Freire AF, Lopes N, et al. Expression and clinical relevance of SOX9 in gastric cancer. Dis Markers. 2019;2019:8267021.
Zhang N, Chai D, Du H, et al. Expression of REG IV and SOX9 and their correlation in human gastric cancer. BMC Cancer. 2018;18:344.
Gnerlich JL, Ding X, Joyce C, et al. Increased SOX9 expression in premalignant and malignant pancreatic neoplasms. Ann Surg Oncol. 2019;26:628–634.
Miura K, Kimura K, Amano R, et al. Analysis of the origin of anaplastic pancreatic cancer and the mechanism of its dedifferentiation. J Hepatobiliary Pancreat Sci. 2017;24:176–184.
Yang Z, Zhang C, Qi W, et al. GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFkappaB in colorectal adenocarcinoma. Exp Cell Res. 2018;373:145–154.
Comperat E, Tissier F, Boye K, et al. Non-Leydig sex-cord tumors of the testis. The place of immunohistochemistry in diagnosis and prognosis. A study of twenty cases. Virchows Arch. 2004;444:567–571.
Kommoss F, Oliva E, Bittinger F, et al. Inhibin-alpha CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol. 2000;31:1055–1061.
Iczkowski KA, Bostwick DG, Cheville JC. Inhibin is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol. 1998;11:774–779.
McCluggage WG, Shanks JH, Whiteside C, et al. Immunohistochemical study of testicular sex cord-stromal tumors, including staining with anti-inhibin antibody. Am J Surg Pathol. 1998;22:615–619.
Mesa H, Gilles S, Datta MW, et al. Comparative immunomorphology of testicular Sertoli and Sertoliform tumors. Hum Pathol. 2017;61:181–189.
Le Guellec S, Soubeyran I, Rochaix P, et al. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol. 2012;25:1551–1558.
Laskin WB, Lasota JP, Fetsch JF, et al. Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases. Am J Surg Pathol. 2015;39:197–205.
Chan EF, Gat U, McNiff JM, et al. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet. 1999;21:410–413.
Lee Y-H, Huang W-C, Hsieh M-S. CTNNB1 mutations in basal cell adenoma of the salivary gland. J Formos Med Assoc. 2018;117:894–901.
Colnot S. Focusing on beta-catenin activating mutations to refine liver tumor profiling. Hepatology. 2016;64:1850–1852.
Rebouissou S, Franconi A, Calderaro J, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different ss-catenin activity associated with liver tumor progression. Hepatology. 2016;64:2047–2061.
Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res. 1999;59:3346–3351.
Kurnit KC, Fellman B, Urbauer D, et al. CTNNB1 (beta-catenin) mutation in grade 1-2 endometrioid endometrial cancer identifies a high-risk subgroup. Gynecol Oncol. 2016;141:17–18.
Kim G, Kurnit KC, Djordjevic B, et al. Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018;31:1553–1559.
Kosmahl M, Seada LS, Jänig U, et al. Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch. 2000;436:473–480.
Reddy S, Cameron JL, Scudiere J, et al. Surgical management of solid-pseudopapillary neoplasms of the pancreas (Franz or Hamoudi tumors): a large single-institutional series. J Am Coll Surg. 2009;208:950–957.
Nguyen NQ, Johns AL, Gill AJ, et al. Clinical and immunohistochemical features of 34 solid pseudopapillary tumors of the pancreas. J Gastroenterol Hepatol. 2011;26:267–274.
Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol. 2000;17:66–80.
Tang LH, Aydin H, Brennan MF, et al. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol. 2005;29:512–519.
Osbun N, Winters B, Holt SK, et al. Characteristics of patients with Sertoli and Leydig cell testis neoplasms from a national population-based registry. Clin Genitourin Cancer. 2017;15:e263–e266.
Deshpande V, Oliva E, Young RH. Solid pseudopapillary neoplasm of the ovary: a report of 3 primary ovarian tumors resembling those of the pancreas. Am J Surg Pathol. 2010;34:1514–1520.
Chen Q, Lu W, Lv W. Overlap of microcystic stromal tumor and primary solid pseudopapillary neoplasm of the ovary. Int J Clin Exp Pathol. 2015;8:11792–11797.
Irving JA, Lee CH, Yip S, et al. Microcystic stromal tumor: a distinctive ovarian sex cord-stromal neoplasm characterized by FOXL2, SF-1, WT-1, cyclin D1, and beta-catenin nuclear expression and CTNNB1 mutations. Am J Surg Pathol. 2015;39:1420–1426.
Xiao GQ, Granato RC, Unger PD. Bilateral Sertoli cell tumors of the testis-a likely new extracolonic manifestation of familial adenomatous polyposis. Virchows Arch. 2012;461:713–715.